CG
RARE icon

Cutler Group’s Ultragenyx Pharmaceutical RARE Stock Holding History

Cutler Group’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-2,100
Closed -$21K – 4203
2023
Q3 		$21K Buy
+2,100
New +$83.2K ﹤0.01% 1997
2022
Q3 		– Sell
-600
Closed -$4K – 5399
2022
Q2 		$4K Buy
+600
New +$36.9K ﹤0.01% 3905
2021
Q1 		– Sell
-2,500
Closed -$46K – 6159
2020
Q4 		$46K Buy
+2,500
New +$297K ﹤0.01% 2076
2019
Q1 		– Sell
-2,000
Closed -$7K – 4620
2018
Q4 		$7K Sell
2,000
-3,000
-60% -$164K ﹤0.01% 2760
2018
Q3 		$32K Sell
5,000
-5,000
-50% -$407K ﹤0.01% 1914
2018
Q2 		$12K Buy
+10,000
New +$646K ﹤0.01% 2548
2017
Q3 		– Sell
-4,600
Closed -$10K – 6542
2017
Q2 		$10K Sell
4,600
-5,500
-54% -$331K ﹤0.01% 4171
2017
Q1 		$63K Sell
10,100
-25,100
-71% -$1.91M ﹤0.01% 2171
2016
Q4 		$162K Buy
35,200
+16,100
+84% +$1.14M 0.01% 1477
2016
Q3 		$99K Buy
19,100
+5,900
+45% +$377K ﹤0.01% 1811
2016
Q2 		$103K Buy
13,200
+1,200
+10% +$77.6K 0.01% 1668
2016
Q1 		$90K Buy
12,000
+5,300
+79% +$347K 0.01% 1713
2015
Q4 		$29K Buy
+6,700
New +$670K ﹤0.01% 3022

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Cutler Group's RARE Position: Q4 2023 in Review

Cutler Group sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2023, closing a stake of 1,010 shares — an estimated $36K sold.

Cutler Group first reported a position in RARE in Q1 2016 and held it in 15 quarters. The position peaked at $753K in Q4 2016. 236 funds tracked by Wall St. Rank hold RARE as of Q4 2023.

  • Cutler Group reported no remaining Ultragenyx Pharmaceutical position as of Q4 2023 after selling out during the quarter.
  • Cutler Group sold 1,010 Ultragenyx Pharmaceutical shares in Q4 2023, an estimated $36K.
  • Cutler Group first reported a position in Ultragenyx Pharmaceutical in Q1 2016 and held it in 15 quarters.
  • Cutler Group's Ultragenyx Pharmaceutical position peaked at $753K in Q4 2016.
  • 236 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2023.

Based on Cutler Group's 13F filing for Q4 2023, filed 18 Jan 2024.